No one can stay awake forever. While we’re awake, our need for sleep gradually increases.
Psychedelics
Study on MDMA for Traumatic Brain Injury Boosted By $1.5M Donation
Wesana Health committed to fund a MAPS study on MDMA for traumatic brain injury.
The Two-Pronged Psychedelics Solution To The Opioid Crisis
Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.
AdvisorShares Launches Psychedelics ETF (Ticker: PSIL)
AdvisorShares' new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol "PSIL") with a focus on small-cap psychedelic stocks.
California Activists Cleared To Collect Signatures For Psilocybin Legalization Ballot Initiative
California activists are now cleared to begin collecting signatures for an initiative to legalize psilocybin mushrooms in the state.
House Could Vote On Psychedelics Research For Military And Marijuana Banking As Part Of Defense Bill
House lawmakers have introduced a series of drug policy-related amendments to defense legislation, including proposals to facilitate research on the benefits of psychedelics for active duty military personnel and to protect banks that service state-legal marijuana businesses.
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.
Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline
Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.
Detroit Voters Will Decide On Psychedelics Decriminalization Ballot Measure In November
Detroit could become one of the next Michigan cities to decriminalize psychedelics, with the reform proposal making the local ballot for this November.
Why Psychedelic Medicine Cures Will Have Greater Profit Potential Than Big Pharma Bandaids
Big Pharma's business model for drug development is all about maximizing profits, not health. Psychedelic medicine can maximize profits AND health.
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
Psychedelics media star, Hamilton Morris is joining Compass Pathways as a full-time consultant on psychedelics research.
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
Atai Life Sciences seeks to integrate digital therapeutics into ketamine-based treatment for TRD, via its digital therapeutic platform, Introspect Digital Therapeutics.
Wesana Health Announces Closing of PsyTech Acquisition
Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.
Novamind Uplists to OTCQB Venture Market
Novamind commences formal trading on the OTCQB under the symbol "NVMDF".